These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12078085)

  • 1. [New drugs that prevent cytotoxicity of Shiga toxins].
    Natori Y
    Nihon Rinsho; 2002 Jun; 60(6):1131-7. PubMed ID: 12078085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
    Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
    J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli.
    Nishikawa K
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):239-47. PubMed ID: 21644029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
    Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
    Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.
    Nishikawa K; Matsuoka K; Kita E; Okabe N; Mizuguchi M; Hino K; Miyazawa S; Yamasaki C; Aoki J; Takashima S; Yamakawa Y; Nishijima M; Terunuma D; Kuzuhara H; Natori Y
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7669-74. PubMed ID: 12032341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of polyunsaturated fatty acids to Shiga toxin cytotoxicity in human renal tubular epithelium-derived cells.
    Sasaki TK; Takita T
    Biochem Cell Biol; 2006 Apr; 84(2):157-66. PubMed ID: 16609696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of cytokines on the expression of Shiga toxin toxicity].
    Nakane A; Sasaki S
    Nihon Rinsho; 2002 Jun; 60(6):1089-94. PubMed ID: 12078078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)--associated hemolytic-uremic syndrome.
    Karch H
    Semin Thromb Hemost; 2001 Jun; 27(3):207-13. PubMed ID: 11446654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive effect of TAK-751S on complications of hemorrhagic colitis (results of clinical study of TAK-751S).
    Ito H; Takeda T; Honda M; Igarashi T; Joh K; Hashizume T; Yamaoka K;
    Jpn J Antibiot; 2002 Apr; 55(2):203-27. PubMed ID: 12071098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy to prevent the progression of enterohemorrhagic Escherichia coli O157 infection to hemolytic uremic syndrome.
    Takeda T
    Jpn J Med Sci Biol; 1998; 51 Suppl():S124-8. PubMed ID: 10211445
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
    Karmali MA
    J Infect Dis; 2004 Feb; 189(3):355-9. PubMed ID: 14745691
    [No Abstract]   [Full Text] [Related]  

  • 12. Shiga toxin-negative attaching and effacing Escherichia coli: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution.
    Bielaszewska M; Middendorf B; Köck R; Friedrich AW; Fruth A; Karch H; Schmidt MA; Mellmann A
    Clin Infect Dis; 2008 Jul; 47(2):208-17. PubMed ID: 18564929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Shiga toxin producing Escherichia coli infection].
    Nakao H
    Nihon Rinsho; 2002 Mar; 60(3):545-50. PubMed ID: 11904971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Enterohemorrhagic Escherichia coli and its infection: from 1977 to 1995].
    Takede Y
    Nihon Rinsho; 1997 Mar; 55(3):635-40. PubMed ID: 9086772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome.
    Trachtman H; Christen E
    Curr Opin Pediatr; 1999 Apr; 11(2):162-8. PubMed ID: 10202627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli.
    Paton JC; Rogers TJ; Morona R; Paton AW
    Infect Immun; 2001 Mar; 69(3):1389-93. PubMed ID: 11179303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.
    Orth D; Grif K; Khan AB; Naim A; Dierich MP; Würzner R
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):235-42. PubMed ID: 17931818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phylogenetic analysis and Shiga toxin production profiling of Shiga toxin-producing/enterohemorrhagic Escherichia coli clinical isolates.
    Li R; Harada T; Honjoh K; Miyamoto T
    Microb Pathog; 2010 Nov; 49(5):246-51. PubMed ID: 20558273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
    Ito K; Hattori M; Matsumoto N
    Nihon Rinsho; 2002 Jun; 60(6):1126-30. PubMed ID: 12078084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome.
    Bielaszewska M; Friedrich AW; Aldick T; Schürk-Bulgrin R; Karch H
    Clin Infect Dis; 2006 Nov; 43(9):1160-7. PubMed ID: 17029135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.